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CFP10 (25mg/mL); A2,A3 negative controls consisted of
cells cultured with medium alone; B2,B3 positive controls
consisted of cells cultured with Con A (25 mg/mL).
Results: The CFP-10 recombinant protein were obtained and
puriﬁed, In-house ELISPOT IFN-g assay using recombinant
CFP-10 antigen show signiﬁcant high frequencies TB speciﬁc
T-cell responses in patients of active TB with or without
HIV infection. there was 100% consistency to the clinical
manifestation, in the HIV(+) group without clinical TB
disease, the rate of positive tests results was 24.7%.
Our results proved that it is indeed true that some of HIV
positive patient have high frequencies of TB speciﬁc T-cell
responses, it could be used in diagnosis of TB diseases,
and it maybe provide a clue to ﬁnd latent TB infection in
Chinese HIV(+) population.
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Background and Aims: Hemophagocytic syndrome (HPS) is a
fatal complication of severe viral infections such as Epstein-
Barr virus (EBV) and recently, SARS CoV, and H5N1 inﬂuenza.
The pathogenesis of HPS is presumed to result from an
enhanced proinﬂammatory cytokine secretion and systemic
macrophage activation. Previously, we demonstrated that
EBV LMP-1 can activate T-cells and upregulate tumor
necrosis factor-alpha and interferon-gamma, mediated
through the NFkB/ATF5/SAP/ERK signaling, to activate
macrophages. Since peroxisome proliferators activated
receptor (PPAR) agonists, regulators of cholesterol
metabolism, have been shown to exhibit profound effects on
the inhibition of proinﬂammatory cytokines and macrophage
activation through NFkB and AP-1 signaling, we adopted a
PPAR-g agonist, rosiglitazone, for the potential therapy of
HPS using a rabbit model of Herpesvirus papio (HVP, an EBV
homologue)-associated HPS.
Materials and Results: In vitro, rosiglitazone was shown
to inhibit macrophage activation and secretion of tumor
necrosis factor-alpha (TNF-a) through inhibition of NFkB
signaling in THP1 cell line. Different doses of rosiglitazone
were then fed to rabbits after intravenous injection of
5×107 copies of HVP virus at different time courses (7
days and 20 days, respectively) of infection. As compared
to the control group which succumbed consistently at
around one month, the 4mg rosiglitazone-treated group
showed signiﬁcant improvement of survival when fed at
early stage (7 days) of infection (p < 0.01), while a higher
dosage (8mg) is needed to achieve therapeutic effect at
advanced stage (20 days) of infection (p < 0.05). The viral
load, TNFa cytokine levels, and laboratory parameters also
showed signiﬁcant improvement in the rosiglitazone-treated
group.
Conclusion: PPAR agonist, in addition to its therapeutic
effect for metabolic syndrome, appears to represent a
potential regimen of new concept for the control of HPS
associated with severe virus infections.
OL-044 HAV seroprevalence among children with 10 24
month ages in Ulaanbaatar
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Background: HAV infection is high endemicity in Mongolia.
The outbreak of acute HAV infection is regular and
wide outbreak usually within 3 4 years interval. Recently,
Mongolian and Japanese researchers established the
seroprevalence of HAV infection in Mongolian adults almost
100%. So, there is urgently needed the HAV vaccination
program in Mongolia.
Aim of study: To determine the age (month) of start for
universal HAV vaccination.
Method and Subjects: In July and August 2008, there were
selected 953 children ages 11 24 months from Chingiltei
district, Ulaanbaatar. More 600 of them were living in the
Mongolian ger (nomad’s tent less comfortable and sanitary
condition than city’s apartment). In all children had not
manifested acute viral hepatitis. In all serum of selected
children were tested anti-HAV-IgG.
Results: There was detected positive of anti-HAV in 20
children of 951. 19 of them living in ger. The table shows
the results by age and sex.
Age Male Female Total
(months) N Anti-HAV+ N Anti-HAV+ N Anti-HAV+
11 12 71 59 130 0
13 14 104 2 94 2 202 4
15 16 74 1 68 143 1
17 18 70 3 58 1 132 4
19 20 57 1 57 2 117 3
21 22 57 2 48 1 108 2
23 24 77 5 59 141 5
Total 510 14 443 6 953 20
Conclusions: 1. The incidence of HAV infection occurred
from 13 month’s age, after wide outbreak. 2. There
is recommended to start HAV vaccination for children,
who living in uncomfortable hygiene condition, before 13
month’s age.
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infections in HIV/AIDS and chronic fatigue
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The aim of this study was to investigate the prevalence
of beta-herpesvirus (HHV-6 and HHV-7) infections among
the HIV/AIDS, chronic fatigue sindrome (CFS) patients in
comparison with blood donors (BD).
Materials and Methods: 52 patients with HIV/AIDS, 49 CFS
and 150 healthy BD were enrolled in the study. Active
and latent/persistent viral infections determined by nPCR:
the presence of viral genomic sequences in PBL DNA only
was deﬁned as latent/persistent infection; sequences in
PBL DNA and blood plasma DNA was deﬁned as active
infection. Concurrent infection with both HHV-6 and HHV-7
was deﬁned as simultaneous presence of both virus genomic
sequences in DNA sample of patient (isolated from PBL or
blood plasma).
Results: PCR analysis did not reveal a signiﬁcant diference
in the prevalence of latent/persistent HHV-7 infection
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between HIV/AIDS patients (37/52) and BD (113/150).
Concurrent latent/persistent HHV-6 and HHV-7 infections
was found much more often in CFS patients (25/49) and
patients with HIV infection (32/52) in comparison with
BD (49/150). The freguency of active HHV-7 infections
signiﬁcally higher in HIV/AIDS patients (19/37) in comparison
with BD (12/113). Active concurrent herpesvirus infections
were observed in HIV/AIDS (10/32) and (9/25) CFS patients
only.
Conclusion: Active infection with both HHV-6 and HHV-7
more frequent in patients with CFS and HIV/AIDS than in
BD.
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OL-046 Efﬁcacy of interferon plus ribavirin therapy in
chronic hepatitis C Patients: A Nepali study
K.C. Sudhamshu*. Liver Unit, National Academy of Medical
Sciences, Bir Hospital, Kathmandu, Nepal
Backgrounda and Aim: Before the availability of pegylated
interferon, interferon therapy in chronic hepatitis C patients
was almost a failure in Nepal. This study was carried out to
determine the efﬁcacy of peg-interferon (2a) plus ribavirin
in Nepali patients.
Method: Thirty-seven consecutive patients with anti HCV
test report were enrolled in the study from April 2004
to December 2007. Chronic hepatitis was conﬁrmed by
raised aminotransferase and presence of HCV RNA by PCR.
Peg-interferon was given in a dose of 180 mcg per week
subcutaneously and dose was adjusted whenever required.
Ribavirin was given in a dose of 800 1000mg/day. Viral load
was repeated after 4th dose, 12th dose, last dose, after 3
month and 6 month of treatment.
Results: Thirty-ﬁve patients showed detectable HCV RNA
by PCR. 30 patients were treated and 29 followed up as 1
patient was lost in follow up. The genotype was 1 in 5, 2
in 9, 3 in 15 patients. 14 patients were super responder (9
type 3 and 5 type 2), while 12 patients were free of virus
after 12 weeks of treatment. End treatment response (ETR)
was 100% and sustained viral response (SVR) was achieved
in 96.5%. Neutropenia was the commonest side effect of
interferon while side effects of ribavirin were not seen.
Conclusions: Peg-interferon and ribavirin was well tolerated
in Nepali patient. ETR was 100% and SVR was 96.5% in small
cohort of patient. 12 weeks therapy may be considered in
type 2 and 3 due to cost factor.
OL-047 Evaluation of anti-HCV samples deemed positive
by chemiluminescent assay using recombinant
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Objective: To conduct conﬁrmative study of anti-
HCV positive samples deemed positive by the second-
tier and third-tier hospitals in China using two fully
automatic chemiluminescent assay instrument, i2000
(ARCHITECT iSystem) and ECI (the Ortho-Clinical
Diagnostics Vitros ECI Anti-HCV with the use of the
CHIRON RIBA (Recombinant Immunoblot Assay) HCV3.0strip
immunoblot assay (SIA) method. For the purpose to evaluate
the rationality positive boundary value of the s/co for
screening the HCV-positive samples. A boundary value of
s/co has been speciﬁed such that any sample screened
positive with s/co ratio greater than the boundary value
would be at least better than 95% truly positive and
therefore need not to undergo conﬁrmatory RIBA test. more
accurate clinical diagnosis of HCV case.
Methods: First, screen out Anti-HCV samples that signal-to-
cutoff (s/co) is 1 20 in the ARCHITECT-i2000 or the Vitros ECI
is 1 35. Then, Chiron RIBA HCV3.0 SIA test was performed
to conﬁrm the Anti-HCV serological results from the two
companies’ instruments. Followed by checking the HCV RNA
with real time PCR. Lastly, perform statistical ROC curve
processing to determine the boundary value of S/CO for
screening anti-HCVpositive samples.
Results: Among the 203 samples, 33 (16%) were conﬁrmed
RIBA negative and HCV RNA negative; 93samples (46%) were
found RIBA positive but in which only 30 (32.3%) samples
were also HCV RNA positive, 77 samples (38%) were found
RIBA indeterminate and HCV RNA negative. In terms of
sensitivity, the ARCHITECT i2000 analyzer is 99% and the
Vitros ECI was found to be 100%. In terms of speciﬁcity, the
ARCHITECT i2000 was found to be 61%; The Vitros ECI to
be 52%. In terms of anti-HCV position predictive value, the
ARCHITECT i2000 analyzer was 100% on s/co > 6.06 while the
Vitros ECI analyzer was 100% on s/co > 12.35.
Conclusion: The criteria of Anti-HCV s/co > 1 is reasonable
for screening test using fully automatic Chemiluminescent
assay with assurance of sensitivity greater than 97%.
The anti-HCV positive samples can be fairly conﬁrmed if
s/co > 6.05 is measured by the architect I2000 analyzer and
s/co > 12.35 is measured by the Vitros ECI analyzer. When
s/co is measured 1.0 6.5 by the ARCHITECT i2000 analyzer
and 1.0 12.5 by the Vitros ECI analyzer, it is suggested to
perform conﬁrmatory RIBA HCV3.0 SIA test if affordable or
perform HCV RNA test, but it may be more realistic to have
periodic re-examination of anti-HCV samples.
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Background and Aims: Helicobacter pylori is a recognized
type I carcinogen. Although there is a mouse model,
where liver ﬁbrosis and hepatocellular carcinoma (HCC)
are induced by infection with H. hepaticus, pathogenicity of
enterohepatic Helicobacter (EHS) in man is still undeﬁned.
Methods: 105 liver biopsies, 60 from patients with chronic
hepatitis C infection and 45 from patients with HCV
infection and HCC were collected in Egypt. Helicobacter
DNA was detected by genus-speciﬁc 16S rDNA PCR and DNA
sequencing (BLAST). Sera were tested for antibodies of
different Helicobacter species (EIA, Immunoblot).
Results: 16S rDNA were found positive in 52.4%. In chronic
HCV without HCC 51.7% while in chronic HCV with HCC
53.3% were positive respectively. H. hepaticus DNA was
detected in chronic HCV without HCC in 35% and in 13.3%
in chronic HCV with HCC. Antibody detection was positive
in patients with hepatitis C without HCC for H. pylori in
67% and H. hepaticus in 22% while antibody detection was
positive for H. pylori in 64% and H. hepaticus in 16% in
patients with HCC.
